Haemophilus Influenzae (Hib) Research 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Role of viable but non culturable cells in patients with cystic fibrosis in the era of highly effective modulator therapy
Cystic fibrosis (CF) is a genetic disease that results in the accumulation and the lack of clearance of dehydrated mucus, mostly in the respiratory system, and hence in bronchiectasis [1]. This thick mucus traps most inhaled bacteria and viruses in the airways, making patients more susceptible to infection. During the first years of life CF sputum cultures show the presence of Haemophilus influenzae and Staphylococcus aureus, presumed to be the source of the lung morbidity in children [2]. Meticulous daily management of lung infections combining airway clearance techniques together with prompt, aggressive antibiotic treatm...
Source: Journal of Cystic Fibrosis - February 28, 2024 Category: Respiratory Medicine Authors: Natalia Cirilli, Valentina Schiavoni, Valentina Tagliabracci, Rosaria Gesuita, Luca Tiano, Benedetta Fabrizzi, Anastasia D'Antuono, Arianna Peruzzi, Nicholas Cedraro, Flavia Carle, Marco Moretti, Luigi Ferrante, Carla Vignaroli, Francesca Biavasco, Gianma Tags: Original Article Source Type: research
Macrolide antibiotics (including azithromycin) for cystic fibrosis
CONCLUSIONS: Azithromycin therapy is associated with a small but consistent improvement in respiratory function, a decreased risk of exacerbation and longer time to exacerbation at six months; but evidence for treatment efficacy beyond six months remains limited. Azithromycin appears to have a good safety profile (although a weekly dose was associated with more gastrointestinal side effects, which makes it less acceptable for long-term therapy), with a relatively minimal treatment burden for people with CF, and it is inexpensive. A wider concern may be the emergence of macrolide resistance reported in the most recent study...
Source: Cochrane Database of Systematic Reviews - February 27, 2024 Category: General Medicine Authors: Kevin W Southern Arturo Solis-Moya Dominiki Kurz Sherie Smith Source Type: research
Macrolide antibiotics (including azithromycin) for cystic fibrosis
CONCLUSIONS: Azithromycin therapy is associated with a small but consistent improvement in respiratory function, a decreased risk of exacerbation and longer time to exacerbation at six months; but evidence for treatment efficacy beyond six months remains limited. Azithromycin appears to have a good safety profile (although a weekly dose was associated with more gastrointestinal side effects, which makes it less acceptable for long-term therapy), with a relatively minimal treatment burden for people with CF, and it is inexpensive. A wider concern may be the emergence of macrolide resistance reported in the most recent study...
Source: Cochrane Database of Systematic Reviews - February 27, 2024 Category: General Medicine Authors: Kevin W Southern Arturo Solis-Moya Dominiki Kurz Sherie Smith Source Type: research
